Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0000899243-20-030026
Filing Date
2020-10-30
Accepted
2020-10-30 20:13:27
Documents
1
Period of Report
2020-10-28

Document Format Files

Seq Description Document Type Size
1 FORM 4 SUBMISSION doc4.html 4  
1 FORM 4 SUBMISSION doc4.xml 4 4071
  Complete submission text file 0000899243-20-030026.txt   5599
Mailing Address 131 DARTMOUTH STREET SUITE 502 BOSTON MA 02116
Business Address 131 DARTMOUTH STREET SUITE 502 BOSTON MA 02116 844-304-2048
Cerevel Therapeutics Holdings, Inc. (Issuer) CIK: 0001805387 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations

Mailing Address C/O CEREVEL THERAPEUTICS HOLDINGS INC. 131 DARTMOUTH STREET SUITE 502 BOSTON MA 02116
Business Address
Bodenrader Mark (Reporting) CIK: 0001830371 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-39311 | Film No.: 201278718